Biosimilars Show Their Muscle as Emerging Pharmaceutical Phenomenon

---

Researched by Industrial Info Resources (Sugar Land, Texas)--Almost the same, but not quite--a biosimilar is just that, similar but not equal to an original biological drug. Unlike generics, biological drugs are too complex be duplicated. And the market for biosimilars is definitely worth watching. Industrial Info is tracking nearly $2 billion worth of active biosimilar facility projects worldwide.

Click on the image at right for a heat map indicating the top countries for investment in biosimilar facilities.

Top earners are starting to lose patent protection for their biosimilars just as the sector is gaining strength, with some reports indicating that it will top $25 billion by 2025. Big Pharma is following the "if you can't beat 'em, join 'em" doctrine, including such majors as Amgen, Merck and Pfizer, all of which have their own biosimilar versions of their own drugs.

Industrial Info Resources (IIR), with global headquarters in Sugar Land, Texas, six offices in North America and 12 international offices, is the leading provider of global market intelligence specializing in the industrial process, heavy manufacturing and energy markets. Industrial Info's quality-assurance philosophy, the Living Forward Reporting Principle™, provides up-to-the-minute intelligence on what's happening now, while constantly keeping track of future opportunities. Follow IIR on: Facebook - Twitter - LinkedIn. For more information on our coverage, send inquiries to info@industrialinfo.com or visit us online at http://www.industrialinfo.com/.